Back to News
Market Impact: 0.38

Zevia Q1 2026 slides: 21% revenue surge, EBITDA turns positive

ZVIAKRAMZNWMTTGTCOSTDGDLTRFIVEMUSA
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsConsumer Demand & RetailProduct LaunchesAnalyst EstimatesCommodities & Raw MaterialsTransportation & Logistics
Zevia Q1 2026 slides: 21% revenue surge, EBITDA turns positive

Zevia delivered Q1 2026 net sales of $46.1 million, up 21.2% year over year and above the $40.37 million consensus, while EPS of -$0.03 beat expectations by 25%. Adjusted EBITDA turned positive at $0.9 million versus a $3.3 million loss a year ago, though gross margin compressed 170 bps to 48.4% on higher aluminum costs. Management reiterated 2026 profitability progress, with guidance calling for EPS of -$0.01 to -$0.03 and revenue of $40.48 million to $45.67 million in upcoming quarters.

Analysis

Zevia’s inflection matters less as a standalone beat and more as a proof point that distribution-led beverage turnarounds can re-rate quickly once unit economics cross a threshold. The important second-order effect is that velocity gains from club and mass can force rivals to spend harder on shelf support just to defend facings, which compresses category economics even if Zevia itself remains small. The mix shift toward larger packs also suggests retailers may be using Zevia as a basket-building incremental item rather than a pure niche health brand, which improves reset durability. The biggest near-term risk is that the margin story is still hostage to input costs and promotional intensity: a 100-150 bps gross margin giveback can erase most of the operating leverage from mid-teens top-line growth at this size. Because the company is only now approaching breakeven, the stock is likely to trade on each quarterly print rather than the full-year narrative; that means the next two earnings cycles are the key catalyst window, not the long-term TAM story. If consumer spending softens, the brand could also face a trade-down effect from premium zero-sugar shoppers moving to private label or larger incumbents with deeper promo budgets. The market is probably underestimating how much optionality comes from channel expansion versus product innovation. If Zevia can continue taking low-penetration channel share, the earnings power scales nonlinearly because fixed SG&A gets leveraged across a broader base, but that works only if retail partners keep giving space to a small brand. Conversely, consensus may be overrewarding the celebrity marketing angle: awareness spikes do not necessarily convert into repeat purchase unless distribution is already available at the shelf. That makes the setup attractive, but only as a staged execution story rather than a clean secular compounder. For competitors, the bigger loser is likely not one specific soda name but the entire adjacent better-for-you set, because Zevia’s sharper taste and packaging reset can pull trial away from functional drinks that rely on health halos but have weaker repeat economics. The most exposed retailers are those with under-penetrated soda assortments and limited ability to rationalize shelf space; once Zevia proves incrementality, they may be forced to widen the set, crowding out lower-rotation SKUs. Near term, that supports a tactical long in ZVIA, but only with tight risk controls because any margin wobble will likely hit the equity multiple hard.